FdaApplication
NDA 214662
Identifiers
- fda_app_no: NDA214662
Properties
| Property | Value |
|---|---|
| applicant_name | MIRUM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2021-09-29 |
Revenue by product
LIVMARLI
| Period | Revenue |
|---|---|
| Q2 2026 | $128.7M |
| Q1 2026 | $113.8M |
| Q4 2025 | $106.4M |
| Q3 2025 | $92.2M |
| Q2 2025 | $88.2M |
| Q1 2025 | $73.2M |
| Q4 2024 | $64.1M |
| Q3 2024 | $59.1M |
| Q2 2024 | $47.2M |
| Q1 2024 | $42.8M |
| Q4 2023 | $41.5M |
| Q3 2023 | $38.7M |
| Q2 2023 | $32.5M |
| Q1 2023 | $29.1M |
| Q4 2022 | $27.9M |
| Q3 2022 | $18.8M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LIVMARLI | MARALIXIBAT CHLORIDE | EQ 19MG BASE/ML | SOLUTION;ORAL |
| LIVMARLI | MARALIXIBAT CHLORIDE | EQ 9.5MG BASE/ML | SOLUTION;ORAL |
2 products